Please select the option that best describes you:
Topics:
Sarcoma • Medical Oncology
What is a preferred regimen for metastatic leiomyosarcoma after failure of doxorubicin/olaratumab and gemcitabine/docetaxel?
No actionable mutations were identified on next generation genomic sequencing.
Answer from: Medical Oncologist at Community Practice
What is a preferred regimen for metastatic leiomyosarcoma after failure of doxorubicin/olaratumab and gemcitabine/docetaxel?
I would consider treatment with either trabectedin or pazopanib.
Sign in or Register to read more